ADMA Biologics, Inc. revised earnings guidance for the full year 2024 and 2025. As the company?s forward-looking business trends build momentum, the company revising financial guidance upwards for both 2024 and 2025, increasing both top and bottom line projections. Based on current market factors, the company now anticipates generating revenues during these periods of more than $355 million and $410 million, respectively.

Similarly, the company is increasing net income guidance to more than $85 million and $135 million for 2024 and 2025, respectively, representing an approximately 60% year-over-year increase.